FDA Approves Awiqli: First Once-Weekly Insulin for Type 2 Diabetes

What Is Awiqli and How Does Once-Weekly Insulin Work?

Awiqli, developed by Novo Nordisk under the generic name insulin icodec, represents a fundamental shift in insulin therapy. Unlike conventional basal insulins such as insulin glargine or insulin degludec that require daily injections, Awiqli's molecular design allows it to bind strongly to albumin in the bloodstream, creating a slow and steady release of active insulin throughout the week. This pharmacokinetic profile delivers consistent glucose-lowering activity over a full seven-day period.

The FDA approval was supported by the ONWARDS clinical trial program, a series of large Phase 3 studies comparing once-weekly insulin icodec to daily basal insulins in various populations of adults with type 2 diabetes. Across these trials, insulin icodec demonstrated non-inferior blood sugar control — measured by HbA1c reduction — compared with daily basal insulin, while maintaining a comparable safety profile. The trials enrolled thousands of participants including those new to insulin therapy and those switching from daily insulin regimens.

Why Is Reducing Injection Frequency Important for Diabetes Management?

Treatment adherence is a persistent barrier in diabetes management. Research published in Diabetes Care and other journals has consistently shown that a substantial proportion of patients on daily basal insulin do not take their injections as prescribed, with missed doses contributing to suboptimal blood sugar control and increased risk of complications. The burden of daily injections — along with factors like needle anxiety, lifestyle disruption, and injection fatigue — is a well-documented driver of non-adherence.

By reducing the number of injections from 365 to 52 per year, Awiqli offers a practical solution to this challenge. For the estimated 6 million Americans with type 2 diabetes who use insulin, and the millions more worldwide, a weekly regimen could simplify treatment routines considerably. Endocrinologists have noted that this kind of innovation could also lower the psychological threshold for patients who are reluctant to initiate insulin therapy — a common phenomenon sometimes called "psychological insulin resistance" — because the prospect of weekly rather than daily injections may be less daunting.

What Should Patients Know About Switching to Weekly Insulin?

The transition from daily to weekly insulin requires careful dose adjustment under medical supervision. In the ONWARDS trials, investigators developed specific protocols for converting patients from their existing daily insulin regimen to the appropriate weekly dose of insulin icodec. Hypoglycemia rates — a key safety concern with any insulin therapy — were generally comparable between weekly and daily insulin groups, though some trials noted modestly higher rates of mild hypoglycemia during the initial adjustment period.

Novo Nordisk has stated that Awiqli will be available in a prefilled pen device designed for ease of use. Pricing and insurance coverage details are still being finalized, and availability in pharmacies is expected in the coming months. Patients interested in once-weekly insulin should discuss their individual treatment goals, current blood sugar control, and overall health status with their endocrinologist or primary care physician to determine if Awiqli is a suitable option for their diabetes management plan.